The President and Chief Executive Officer of Lyell Immunopharma is Dr. Lynn Seely, who has steered the enterprise in its executive leadership role. Bringing extensive medical, clinical development, and executive experience from previous leadership roles at major biotechnology and pharmaceutical organizations—including serving as CEO of Myovant Sciences and Chief Medical Officer of Medivation—she guides Lyell's strategic focus on cell-based cancer therapies. Her leadership centers on advancing the company's T-cell reprogramming platforms through critical clinical trials and preparing for future commercialization milestones.